OncoMark is focused on the development of novel panels of cancer biomarkers to aid treatment decisions and allow more tailored patient management, ultimately improving the quality of life for cancer patients.

Product

OncoMasTR is a novel prognostic test for early stage breast cancer. This gene expression profiling test accurately estimates the risk of recurrence for early-stage breast cancer patients. This test will aid the clinicians in determining the best treatment options for their patients. read more »

Gene expression profiling test for early-stage breast cancer prognosis

Latest News

June 2017 - Champions of EU Research Award

OncoMark wins a Champions of EU Research award

OncoMark CEO Des O'Leary was awarded an Ireland's Champions of EU Research award from Enterprise Ireland at an event held in the Royal Hospital Kilmainham yesterday (Wednesday 28th June 2017).

May 2017 - Review published on MTRs

OncoMark Researchers Shed Light on the Discovery and Validation of Master Transcriptional Regulators in Cancer

OncoMark researchers have recently had a review published in the American Association for Cancer Research (AACR) journal, Cancer Research, describing how the reverse engineering of transcriptional networks using gene expression data enables the identification of genes that underpin the development and progression of different cancers.

March 2017 - IACR Cancer Research Medal

Prof. William Gallagher Awarded Prestigious Medal for Outstanding Contribution to Irish Cancer Research

Congratulations to Professor William Gallagher, who was the inaugural recipient of the Irish Association of Cancer Research (IACR) Cancer Research Medal at the annual IACR Conference held in Kilkenny on 22nd-24th February 2017.

February 2017 - €2.1 Million Investment

OncoMark Secures €2.1 Million Investment to Commercialise New Diagnostic Test for Breast Cancer

OncoMasTR test to launch in 2018 and will reduce the number of patients receiving unnecessary chemotherapy